With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

Vertex Pharmaceuticals VRTX announced that the European Commission has approved Alyftrek ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® ...

VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...

Alyftrek is approved to treat people ages 6 and older who have the genetic condition called cystic fibrosis. Cystic fibrosis happens because of a change in a gene on chromosome 7.

ALYFTREK and TRIKAFTA are not recommended in patients with moderate hepatic impairment and should only be considered when there is a clear medical need and benefit outweighs risk.

Alyftrek and Journavx — The Two Big Launches. According to JPMorgan analyst Jessica Fye, investors will be laser-focused on the company’s two big launches: Alyftrek and Journavx.

Alyftrek, a Key Product in VRTX's CF Portfolio. Vertex holds a dominant position in the CF market. Its CF sales continue to grow, driven by the demand growth of the blockbuster drug, Trikafta ...

ALYFTREK is approved in the EU for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane ...

ALYFTREK should only be considered when there is a clear medical need and benefit outweighs risk. If ALYFTREK is used, monitor patients closely. If TRIKAFTA is used, use with caution at a reduced ...